Evidence map›Paper›PMID 41083961›Full record

ArticleBMC cancer2025

The association between serum uric acid and survival outcomes in patients with metastatic renal cell carcinoma treated with targeted therapy.

Oktay Halit Aktepe, Faruk Recep Ozalp, Eda Caliskan Yildirim, Mehmet Cihan Icli, Hatice Altas, Canberk Sencan, Ahmet Melih Arslan, Mehmet Sinan Akarca, Huseyin Salih Semiz, Aziz Karaoglu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Oktay Halit AktepeDepartment of Medical Oncology, Dokuz Eylul University, Izmir, Turkey. oktayhalit.aktepe@deu.edu.tr.ORCID http://orcid.org/0000-0003-3540-0701
Faruk Recep OzalpDepartment of Medical Oncology, Dokuz Eylul University, Izmir, Turkey.
Eda Caliskan YildirimDepartment of Medical Oncology, Dokuz Eylul University, Izmir, Turkey.
Mehmet Cihan IcliDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Hatice AltasDepartment of Internal Medicine, Dokuz Eylul University, Izmir, Turkey.
Canberk SencanDepartment of Medical Oncology, Dokuz Eylul University, Izmir, Turkey.
Ahmet Melih ArslanDepartment of Medical Oncology, Dokuz Eylul University, Izmir, Turkey.
Mehmet Sinan AkarcaDepartment of Medical Oncology, Dokuz Eylul University, Izmir, Turkey.
Huseyin Salih SemizDepartment of Medical Oncology, Dokuz Eylul University, Izmir, Turkey.
Aziz KaraogluDepartment of Medical Oncology, Dokuz Eylul University, Izmir, Turkey.
Mustafa ErmanDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Suayib YalcinDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSerum uric acid (SUA), the end product of purine metabolism, may play a crucial role in the biology of several cancers, including renal cell carcinoma (RCC). However, data on the association of SUA with metastatic RCC (mRCC) survival are limited. Thus, we evaluated the prognostic importance of baseline serum uric acid in mRCC patients treated with targeted therapy.

methodsThe SUA level of 5.8 mg/dL was determined as the optimal cut-off point in predicting OS in the receiver operating characteristic curve. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS) in SUA groups. Cox proportional hazard models were performed to evaluate the association between SUA and survival outcomes.

resultsA total of 290 patients with a median age of 61 were included in the study. The median PFS and OS of all patients were 11.6 months and 45 months, respectively. The low-SUA group had superior PFS and OS times than the high-SUA group (16.2 months vs. 8.8 months, p < 0.001 for PFS; 92 months vs. 24.7 months, p < 0.001 for OS, respectively). The multivariate analysis indicated that high SUA levels remained an independent predictor of both PFS and OS after controlling for multiple confounders, including the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk scoring system (HR:1.79, 95%CI 1.35-2.37, p < 0.001 for PFS; HR: 3.32, 95%CI 2.33-4.72, p < 0.001 for OS).

conclusionsOur study highlights a noteworthy association between high SUA levels and adverse survival outcomes in patients with RCC treated with targeted therapies.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsUric AcidAdultAgedAged, 80 and overFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMolecular Targeted TherapyNeoplasm MetastasisPrognosisProgression-Free SurvivalRetrospective StudiesUric AcidMetastatic renal cell carcinomaPrognosisTargeted therapyUric acid

Identifiers

PMID41083961
PMCPMC12519814

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.